More highlights from ESMO Congress

2 October 2012

In further news coming out at the European Society of Medical Oncology (ESMO) Congress taking place in Vienna, Austria (see also The Pharma Letter October 1), USA-based ImmunoGen (Nasdaq: IMGN) announced overall survival data for its trastuzumab emtansine (T-DM1) Phase III EMILIA trial, showing that the product reduced the risk of death by 32% compared to the standard-of-care treatment arm of the trial.

Trastuzumab emtansine is in global development by Swiss drug major Roche under an agreement between its subsidiary Genentech and ImmunoGen and utilizes ImmunoGen’s TAP technology with the trastuzumab antibody. Genentech and Roche have applied for marketing approval of trastuzumab emtansine in the USA and Europe, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK